COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
Top Cited Papers
Open Access
- 6 July 2021
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 11 (7), 993
- https://doi.org/10.3390/biom11070993
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major concern for global human health. The challenge to restrain the COVID-19 pandemic is further compounded by the emergence of several SARS-CoV-2 variants viz. B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta), which show increased transmissibility and resistance towards vaccines and therapies. Importantly, there is convincing evidence of increased susceptibility to SARS-CoV-2 infection among individuals with dysregulated immune response and comorbidities. Herein, we provide a comprehensive perspective regarding vulnerability of SARS-CoV-2 infection in patients with underlying medical comorbidities. We discuss ongoing vaccine (mRNA, protein-based, viral vector-based, etc.) and therapeutic (monoclonal antibodies, small molecules, plasma therapy, etc.) modalities designed to curb the COVID-19 pandemic. We also discuss in detail, the challenges posed by different SARS-CoV-2 variants of concern (VOC) identified across the globe and their effects on therapeutic and prophylactic interventions.This publication has 216 references indexed in Scilit:
- A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal diseaseNature Medicine, 2012
- Sustained Remission of Multicentric Castleman Disease in Children Treated with Tocilizumab, an Anti-Interleukin-6 Receptor AntibodyMolecular Cancer Therapeutics, 2012
- Systemic Lupus ErythematosusThe New England Journal of Medicine, 2011
- Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destructionAnnals Of The Rheumatic Diseases, 2011
- Inflammatory Bowel DiseaseThe New England Journal of Medicine, 2009
- Nosocomial infections in patients with cancerThe Lancet Oncology, 2009
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004
- Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes miceProceedings of the National Academy of Sciences of the United States of America, 2004
- EFFICACY OF IMMUNE PLASMA IN TREATMENT OF ARGENTINE HÆMORRHAGIC FEVER AND ASSOCIATION BETWEEN TREATMENT AND A LATE NEUROLOGICAL SYNDROMEThe Lancet, 1979